Axsome Therapeutics Inc is a New York-based biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. Its product lineup includes Auvelity for major depressive disorder and Sunosi for narcolepsy or obstructive sleep apnea-related daytime sleepiness. The company is also advancing several drugs through clinical trials, targeting conditions like Alzheimer's disease agitation, migraine, narcolepsy, fibromyalgia, and more. Axsome's commitment to addressing unmet medical needs in mental health and neurological conditions underscores its research-driven approach.
Oversold shares of Nike (NYSE: NKE | NKE Price Prediction) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that…
